Clinical Trials
27 trialsNCT01871727 2024-11-13
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Eisai Inc.
Phase 3 Completed
NCT03493451 2024-10-26
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Phase 2 Completed
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT01226472 2024-04-25
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01728805 2024-04-25
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01579318 2023-05-15
CTCL
OncoSec Medical Incorporated
Phase 2 Terminated
NCT00002663 2023-02-13
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Phase 1/2 Completed
NCT01607892 2023-01-26
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT02314247 2023-01-26
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02448381 2022-04-15
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix
Phase 3 Completed
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00425555 2021-08-20
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Novartis
Phase 2 Completed
NCT00490776 2021-08-18
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
Phase 2 Terminated
NCT02676778 2021-07-15
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT03292406 2021-04-08
CTCL
Galderma R&D
Phase 2 Completed
NCT01578499 2021-01-05
ALCANZA
Takeda
Phase 3 Completed
NCT00744991 2020-10-19
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT02296164 2020-03-04
PROVe
Helsinn Therapeutics (U.S.), Inc
Completed
NCT02567656 2020-01-13
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Rhizen Pharmaceuticals SA
Phase 1 Completed
NCT01007448 2019-11-12
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
Phase 4 Completed
NCT00106431 2019-10-30
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Celgene
Phase 2 Completed
NCT01433731 2016-03-24
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
TetraLogic Pharmaceuticals
Phase 1 Completed
NCT00274651 2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2 Terminated
NCT00724984 2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00168064 2012-10-31
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Yaupon Therapeutics
Phase 2 Completed